Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma ( RRMM ): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis
American Journal of Hematology · 2026-08 · 101 (8) · 1928-1937
DOI: 10.1002/ajh.70376 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 19.05.2026. Verfasst von Murali Janakiram und 20 weiteren Autor:innen. Beteiligte Einrichtung: City of Hope National Medical Center, Duarte, California, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Talquetamab is a GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). This is the first real‐world study to comprehensively report muco‐cutaneous toxicities, infections, and efficacy of talquetamab in 151 patients across five countries with the longest follow‐up reported enabling better efficacy and toxicity estimates. The median age was 64 years; high‐risk cytogenetics were present in 42%; ECOG ≥ 2 in 22%; 12% had creatinine clearance < 30; and 55% would not have met MonumenTAL‐1 eligibility. Patients received a median of 6 prior lines of therapy, 53% were penta‐refractory, and 75% received prior BCMA therapy. Talquetamab was associated with skin toxicity in 39.7%, nail toxicity in 75.5%, dysgeusia in 60.4%, and oral toxicities in 62.9%, with grade ≥ 3 events uncommon (≤ 4%) and dose interruptions infrequent (9.6% for skin toxicity, 6.9% for dysgeusia, and 4.0% for oral toxicities). These findings underscore the need for improved supportive care for muco‐cutaneous toxicities. In multivariate analysis, only platelet count < 50 (HR 1.8, 95% CI 1.15–2.83) was associated with inferior PFS, while penta‐refractory status, absolute lymphocyte count < 0.4, and prior BCMA‐targeted therapy were not statistically significant. With a median follow‐up of 12.7 months, the overall response rate was 67.6%, median progression‐free survival was 7 months, and 12‐month overall survival was 65%. This study shows that talquetamab efficacy is maintained in a heavily pretreated real‐world population with high prior BCMA exposure and notable comorbidity burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- City of Hope National Medical Center, Duarte, California, USA.
- Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
- University of California, San Francisco, California, USA.
- University College London, London, UK.
- University of Complutense, Madrid, Spain.
ORCID-Profile: Murali Janakiram, Carlyn R Tan, Rakesh Popat, Efsthathios Kastritis, Magdalene Corona
Förderung
- NCI NIH HHS
Zitieren
APA
Janakiram, M., Tan, C. R., Mian, H., Huang, C. Y., Popat, R., Martínez-Lopez, J., Kastritis, E., Chng, W. J., Kapoor, P., Dave, M., Bal, S., Garderet, L., Corraes, A. M. S., Riedhammer, C., Steinbrunn, T., Corona, M., Nagarajan, C., Einsele, H., Martin, T., …, & Lin, Y. (2026). Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma ( RRMM ): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis. American Journal of Hematology, 101(8), 1928-1937. https://doi.org/10.1002/ajh.70376
Vancouver
Janakiram M, Tan CR, Mian H, Huang CY, Popat R, Martínez-Lopez J, et al. Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma ( RRMM ): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis. American Journal of Hematology. 2026;101(8):1928-1937. doi:10.1002/ajh.70376
BibTeX
@article{Janakiram2026,
author = {Janakiram, Murali and Tan, Carlyn R and Mian, Hira and Huang, Chiung-Yu and Popat, Rakesh and Martínez-Lopez, Joaquín and Kastritis, Efsthathios and Chng, Wee-Joo and Kapoor, Prashant and Dave, Mrugakshi and Bal, Susan and Garderet, Laurent and Corraes, Andre De Menezes Silva and Riedhammer, Christine and Steinbrunn, Torsten and Corona, Magdalene and Nagarajan, Chandramouli and Einsele, Hermann and Martin, Tom and Krishnan, Amrita and Lin, Yi},
title = {Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma ( RRMM ): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {8},
pages = {1928--1937},
doi = {10.1002/ajh.70376}
}
EUVIMED